IAG is Leading AI powered Drug Development and Precision Medicine.


IAG, Image Analysis Group is comprised of Image Analysis, Ltd. (HQ: London, UK), Image Analysis, Inc. (HQ: Philadelphia, PA, USA) and Venture Partners. IAG is unique partner to life sciences companies. Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure.

At IAG, we are committed to helping our biotech and pharma partners to efficiently develop novel life-changing medicines, by accelerating their R&D pipelines through advanced analytics, IAG’s technology solutions and imaging contract research services.

IAG’s foundation is in software development, use of Artificial Intelligence and data sciences applied to medical imaging.

Today, IAG leads the industry when it comes to optimizing clinical trial designs with imaging-based methodologies that can accelerate go / no-go efficacy decisions for emerging therapeutics and enrich patient selection in musculoskeletal, oncology, immunology, rheumatology, CNS and rare disease trials.

IAG’s proprietary platform DYNAMIKA, developed to maximize efficiencies of handling imaging data in multi-centre clinical trials is used by blue-chip pharmaceutical companies, CROs, biotechnology companies, and academics world-wide.

Smart use of novel approaches for central image review and our modern trial infrastructure ensure the speed and cost-effectiveness of phase I-VI trial execution, while delivering true insights about novel mechanisms of action and patients’ response, in real-time.

IAG’s teams within our three divisions – strategy, operations and bio-partnering together with our world-class Scientific Advisory Board closely work with our life science partners to address their goals of smart trial design, efficient execution and monetization of their assets through successful partnerships.

We are here to create successful partnerships and to see more patients cured with the drugs, that we can help you to develop.


While studying for her PhD at Leeds, UK Olga Kubassova began work on commercialising her research. She was the first winner of the Sir Peter Thompson Enterprise Award, and ten years on her bright idea has developed into a global business with HQ in  London, UK and Philadelphia, USA. In this video, Olga talks about the encouragement she received in establishing the business, the fast growing team and endorsement from blue chip partners, which include top 10 pharmaceutical companies, innovative biotech and medtech players and IAG’s own portfolio companies.


Targeted market assessment, patented benchmarking libraries, analytics platform and the most comprehensive expert advisory board  help our clients to formulate clear strategy and design the optimal trial for early go / no go decisions.


Integration of cloud platform, study-specific biomarkers with experience of IAG’ commercial and operational team ensures meeting your business objectives for growth or partnering, fast execution of projects and scientific credibility of the outcomes.


An independent division of IAG seeks to partner with biotech companies with promising compounds at early stages of clinical development or academics with IP ready for commercialization.

Imaging Services in Clinical Trials

We strategically use imaging, such as MRI, CT, and PET to accelerate drug development and lower investment risks. Whether you are entering a phase I/II and need early robust efficacy data or preparing a successful H2H or superiority trial, our science, operations and technology teams will work with you to develop the right solution

DYNAMIKA, Leading Trial Platform

IAG’s cloud platform for robust imaging data management in multi-centre trial setting and central review. One comprehensive software system to control trial progress, conduct central reads and use built-in AI for earlier read-outs and decision support.



Innovating together with promising life science companies and securing successful partnering arrangements has yielded spectacular results over the past 10 years. As a trusted partner to many biotech and pharma companies, IAG’s team is proud to share your words.


Since 2007, over 2000 articles were published by IAG’s team and advisory board to cover scientific discoveries, technology break-throughs and special cases. We list here some critically important papers and abstracts.


From the Technology Innovation to the Entrepreneur of the Year, IAG’s team, its founder-CEO and its industry disrupting technology platform DYNAMIKA won 22 awards since 2007. We share, with pride and thanks!

Quality Management

Rigorous quality standards, compliance to 21 CFR Part 11, ISO13485. Our Quality Management System is certified by the British Standards Institute (BSI).